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Background: Patients under antipsychotic treatment for schizophrenia commonly exhibit poor adherence to
treatment, high rates of treatment discontinuation, and frequent treatment changes. The ETOS study aimed to
identify the reasons leading physicians to decide to switch antipsychotic treatment in outpatients with
schizophrenia and to evaluate the outcome of this switch.
Methods: ETOS was an observational 18-week (four visits) study in outpatients 18 to 65 years old, diagnosed with
schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders - 4th edition criteria at least
6 months prior to enrolment, who were initiated on a new antipsychotic monotherapy treatment within the
2 weeks prior to enrollment. A total of 574 patients were recruited by 87 hospital- and office-based physicians.
Ethical approval was obtained prior to study initiation (NCT00999895).
Results: The final analysis included 568 patients, 39.0 ± 11.2 years old with mean disease duration of 11.7 years.
The male-to-female ratio was 53:47. The main reason for switching antipsychotic treatment was lack of tolerability
(n = 369, 65.0%), followed by lack of efficacy (n = 249, 43.8%). Following treatment switch, 87.9% of patients
(n = 499) showed meaningful clinical benefit by achieving a Clinical Global Impression-Clinical Benefit score of ≤4
at the final visit. By the end of the study, total Positive and Negative Syndrome Scale, Clinical Global Impression-
Improvement, Clinical Global Impression-Severity, and Simpson-Angus Scale scores demonstrated significant mean
decreases of 31.69, 0.70, 1.14, and 11.30, respectively (all p < 0.0001). Treatment adherence remarkably improved.
Conclusion: In the ETOS study, switch of antipsychotic monotherapy for reasons relating to lack of efficacy and/or
tolerability was associated with significantly improved clinical benefit and significant increase of patients' adherence
to treatment.
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Schizophrenia is a chronic, severely disabling psychiatric
illness with a lifetime risk ranging from 0.2% to 0.7%
and an incidence of 15.2 per 100,000 per year [1,2].
Treating schizophrenia is usually a lifelong process that
poses an enormous disease burden on the patient and
the caregiver and a great challenge for the physician.
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stated.crucial factors for the long-term clinical management of
schizophrenia and are key determinants for good
prognosis [3-6].
Schizophrenic patients under antipsychotic treatment
have been shown to exhibit poor adherence and high rates
of treatment discontinuation, often within the first year of
treatment commencement [7-11]. It has been shown that
almost half of the patients with schizophrenia or schizoaf-
fective disorder on antipsychotic medication take less than
70% of the prescribed doses [12]. Partial or no adherence
to treatment has been associated with increased risk ofal Ltd. This is an Open Access article distributed under the terms of the Creative
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clinical and functional deterioration [13-15]. Poor treat-
ment adherence and high discontinuation rates often lead
to frequent treatment changes, as it is generally accepted
that subjects who are not responding to an agent belonging
to a particular class of psychotropic drugs or who experi-
ence adverse events may show a better response to another
agent of the same or other therapeutic class [16,17].
Switching to improve efficacy and/or tolerability has
been studied in several clinical trials. A significant im-
provement in the Positive and Negative Syndrome Scale
(PANSS) scores as well as in patients' metabolic profile
has been observed by switching from conventional anti-
psychotics, olanzapine, or risperidone to ziprasidone
over a 6-week clinical study [18]. Cognitive function has
been shown to improve by switching from conventional
or atypical antipsychotics to ziprasidone [19] or to olan-
zapine [20]. Ganesan and colleagues have shown that
switching from other antipsychotics to quetiapine XR is
associated with an improved efficacy and tolerability
profile [21]. Furthermore, switching to quetiapine from
typical or atypical antipsychotics has been found to sig-
nificantly reduce extrapyramidal symptoms [22], and
switching to quetiapine from another atypical agent has
been proposed in cases of new-onset tardive dyskinesia
[23,24]. Nonetheless, the question regarding whether a
switch in antipsychotic treatment improves the patients'
outcome still remains unanswered. Improvement in pa-
tient outcome is probably related to the therapeutic
choice made each time [17].
Atypical antipsychotics are considered to be better toler-
ated than typical antipsychotic agents and are currently
the mainstay of schizophrenia treatment. However, atyp-
ical antipsychotics have been associated with long-term
adverse effects on patients' weight, serum glucose levels,
and serum lipids [25-28]. In order to develop a patient-
individualized switching strategy, decision making should
be based on key patient illness characteristics, specifically
on the patient's symptomatology, comorbidities, and side
effects experienced with previous antipsychotics [16].
The ETOS study aimed to identify the reasons leading
physicians to change the single antipsychotic treatment
of outpatients with schizophrenia to another single anti-




ETOS was an open-label, prospective, observational
study that enrolled 574 outpatients with schizophrenia,
who required a change in their primary antipsychotic
medication for any reason according to their physician's
discretion. The study was conducted between October
2009 and September 2010 in 87 sites all over Greece; tenof these sites were hospital-based, while the remaining
77 were private office-based practices.
The study was conducted in accordance with the Declar-
ation of Helsinki and approved both by the Scientific
Committee/Administrative Council (IRBs) of the participat-
ing hospitals and the Greek National Organization of
Medicines. All aspects of treatment and care of patients
were determined by the treating physicians. Ethical approval
was obtained prior to study initiation (NCT00999895).
Study population
Male or female outpatients were included in the study if
they (1) were aged between 18 to 65 years, (2) had a
diagnosis of schizophrenia according to Diagnostic and
Statistical Manual of Mental Disorders - 4th edition
(DSM-IV) at least 6 months prior to enrollment, and (3)
were initiated on a new antipsychotic monotherapy
treatment within the preceding 2 weeks. All patients
were receiving antipsychotic monotherapy before switch-
ing to a new antipsychotic treatment. The provision by
the patient of a written informed consent was a pre-
requisite for entering the study.
Exclusion criteria were as follows: (1) diagnosis of any
other psychiatric condition (except from schizophrenia)
as per DSM-IV Axis Ι, concomitant organic mental dis-
order or mental retardation, (2) substance abuse or de-
pendence (with the exception of nicotine dependence) as
defined by DSM-IV criteria and not in full remission, (3)
pregnancy or breastfeeding, and (4) participation in an-
other clinical study.
Patient assessments
The study was conducted in the real-world clinical prac-
tice. Patients were observed by their treating physicians
during four scheduled visits: on day 0 (baseline), week 6
(visit 2), week 12 (visit 3), and week 18 (final visit), over
a period of 18 weeks. Sociodemographic and baseline
characteristics, including age, anthropometric, and med-
ical history, were recorded during the baseline (day 0)
visit. Laboratory results, when available, including those
that led to the decision of treatment switch and con-
comitant medications were recorded throughout the
study. Clinical benefit from treatment switching which
was the primary study objective was assessed with the
Clinical Global Impression-Clinical Benefit (CGI-CB)
scale by calculating the percentage of subjects achieving
a score of ≤4 (1 indicates the greatest improvement) at
the end of the study.
The study also aimed to capture the detailed reasons
which led the physicians to the decision of switching
antipsychotic treatment, as well as the therapeutic man-
agement options. Thus, during the baseline visit, physi-
cians recorded the reasons which led them to switch the
patients' previous antipsychotic monotherapy as well as
Table 1 Baseline demographic and clinical characteristics







Elementary school 71 12.5
Junior high school 121 21.3
High school 217 38.3
Technical institution 90 15.9
University 68 12.0
Living conditions
Lives alone 86 15.1
Lives with spouse 101 17.8
Lives with children or
relatives others
372 65.5
Nursing home, institution 8 1.4
Lives with wife and children 1 0.2
Age (years) 39.0 ± 11.2
(18.0 to 65.0)
BMI (kg/m2) 27.6 ± 4.7
(17.7 to 50.8)
Time since diagnosis (year) 11.7 ± 12.3
(0.5 to 41.0)
PANSS 249 92.9 ± 28.2
CGI-S 568 4.1 ± 1.1
SAS 111 14.5 ± 9.6
BARS 568 86.1 ± 18.2
BMI, body mass index; PANSS, Positive and Negative Syndrome Scale; CGI-S,
Clinical Global Impression-Severity; SAS, Simpson-Angus Scale; BARS, Brief
Adherence Rating Scale.
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tion. In patients who demonstrated lack of efficacy as
the reason for treatment switching, the Positive and
Negative Syndrome Scale (PANSS) was used to evaluate
the effect of the new treatment. On the other hand, in
patients who demonstrated lack of tolerability, the
Simpson-Angus Scale (SAS) scores were recorded in
cases where the reason for switching was extrapyramidal
symptoms, while measurements of body weight, were
employed for those switching due to problems with their
body weight. Furthermore, when the reason for switch-
ing was abnormal laboratory values, the respective vari-
able, i.e., serum glucose levels, prolactin levels, and
serum lipids were evaluated. Standardized efficacy pa-
rameters such as the CGI-Improvement (CGI-I) and
CGI-Severity (CGI-S) were evaluated for all patients.
Compliance to the new treatment was also evaluated for
all patients by the use of Brief Adherence Rating Scale
(BARS). The aforementioned secondary variables were
monitored at the baseline visit (except for the CGI-I
score), the two follow-up visits and the final visit. Due to
the non-interventional nature a comprehensive safety as-
sessment was not conducted.
Statistical analysis
Statistical analysis was performed in the study popula-
tion attending all follow-up visits (Per Protocol
Population-PP) using the statistical software SPSS 17.0.
The analysis of data was based mainly on descriptive
statistical methods. Continuous variables are presented
as means of measures of central tendency and disper-
sion. Categorical variables are presented as frequency
distribution tables. The relationship between categorical
variables is illustrated using contingency tables. The stat-
istical significance of the changes in the evaluation scales
and laboratory measurements between the first and final
visit was assessed by means of a paired t test. The 95%
confidence intervals were calculated regarding the esti-
mation of the primary endpoint.
Results
Patients’ characteristics
Of the 574 patients initially enrolled, 568 patients
(98.95%) comprised the Per Protocol (PP) population
used in the present analysis. The six patients not in-
cluded in the PP population were either lost to follow-
up or did not attend all study visits. Specifically, of the
574 patients attending the first visit, 571 attended the
second visit, 569 the third visit, and 569 the final visit
(with one patient returning for the final visit after miss-
ing visits 2 and 3).
Baseline sociodemographic and clinical characteristics
for the study population are presented in Table 1. The
study population had a mean age of 39 ± 11.2 years witha male-to-female ratio of 53:47. The mean time since
schizophrenia diagnosis was 11.7 years. The majority of
the study population was urban residents (70.1%), mar-
ried or living with a spouse and/or children or relatives
(83.5%), at least high school graduates (66.2%), and un-
employed (61.2%). The most common concomitant dis-
eases (>1%) were psychiatric disorders - other than
schizophrenia - (32.7%), neurological comorbidities
(12.7%), vascular disorders (5.8%), and metabolic and
nutritional disorders (5.1%). The majority of the patients
(n = 371, 65.3%) were receiving at least one concomitant
medication during the 18-week study period.
Reasons for switching antipsychotic treatment
The main reason for leading physicians' to switching
antipsychotic treatment in schizophrenic outpatients
was lack of tolerability (n = 369, 65.0%), followed by lack
of efficacy (n = 249, 43.8%). Notably, 8.8% (n = 50)
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and efficacy. The two major tolerability reasons were
weight gain (40.4%) and extrapyramidal symptoms
(30.1%) (Table 2). Patients who changed treatment for
tolerability reasons (n = 369) were mainly switched from
olanzapine (37.4%) and risperidone (24.7%). Patients
who switched due to lack of efficacy (n = 249) were
mainly (>10%) switched from aripiprazole (22.1%), ris-
peridone (21.3%), olanzapine (16.5%), and ziprasidone
(12.9%).
Current antipsychotic treatment
Patients who were switched from their previous anti-
psychotic treatment due to efficacy reasons were mainly
switched to quetiapine (50.2%), risperidone (8.8%), aripi-
prazole (7.6%), olanzapine (7.6%), amisulpride (7.2%),
and paliperidone (6.4%). Patients who were switched due
to tolerability reasons were mainly switched to quetia-
pine (58.5%), aripiprazole (10.8%), olanzapine (9.8%),
paliperidone (6.2%), and ziprasidone (5.4%).
Clinical benefit from switching to another antipsychotic
monotherapy
The physician's strategy to manage their schizophrenic
patients who presented with suboptimal efficacy or toler-
ability by switching the antipsychotic treatment resulted
in a meaningful clinical benefit for 87.9% (95% CI, 84.9








In combination with lack of efficacy 50 8.8
Total 369 65.0
Lack of tolerability, analytically (n = 369)*
Weight gain 149 40.4
Extrapyramidal symptoms 111 30.1
Lack of tolerance 42 11.4
Hyperprolactinaemia 39 10.6
Hyperlipidaemia and/or glucose increase 24 6.5
Stress/insomnia/anxiety/akathisia 16 4.3
Sleepiness/drowsiness 12 3.2
Gynecological dysfunctions 6 1.6
Sexual disorders 6 1.6
Other adverse events 10 2.7
Asterisk ‘*’ denotes more than one of these reasons may have been selected.CGI-CB score of ≤ 4 at the final visit. Clinical benefit,
i.e., CGI-CB ≤4, was achieved by 86.9%, 89.0%, and
84.0%, respectively, of patients who switched therapy for
efficacy, tolerability, or for both reasons. Additionally, by
the end of the study, the mean CGI-I and CGI-S scores
demonstrated a significant mean decrease from baseline
of 0.71 (95% CI, 0.76 to 0.64; p < 0.001) and 1.14 (95%
CI, −1.22 to −1.05; p < 0.001), respectively (Figure 1).
Efficacy as reason for switching
The patients whose physicians decided to change their
therapeutic management due to efficacy reasons had a
mean total PANSS baseline score of 92.9 (± 28.2) (n = 249).
At the end of the follow-up period, 18 weeks following the
change of their treatment, the total PANSS scores were sig-
nificantly improved showing a mean decrease from baseline
of 31.69, (95% CI, −34.42 to −28.96; p < 0.0001). The mean
values of PANSS at baseline are presented in Table 1, while
an overview of the aforementioned efficacy measures at
each visit is shown in Figure 1.
Tolerability assessments
All patients who switched due to extrapyramidal symp-
toms were evaluated with SAS (n = 111) at baseline and
subsequent study visits and presented a significant im-
provement, with a mean decrease in SAS score of 11.30
(95% CI, −13.09 to −9.51; p < 0.0001). Following treat-
ment switch, body weight, glucose, total cholesterol, and
prolactin levels showed significant decreases by the end
of the study (Table 3). In particular, measurements in
body weight were recorded for those patients (n = 149)
experiencing clinically significant weight gain with their
previous antipsychotic medication and showed a mean
decrease of 6.85 kg, (95% CI, −7.75 to −5.96; p < 0.0001)
by the end of the study. Prolactin levels were also signifi-
cantly decreased by 62.3 ng/mL (95% CI, −76.7 to −47.9;
p < 0.0001) in those patients who had switched due to
hyperprolactinaemia (n = 39).
Treatment adherence
Adherence to treatment was evaluated in the total study
population using the BARS scores (Table 1, Figure 1).
Treatment switch was accompanied by significant im-
provement in adherence, as shown by a mean change in
BARS scores of 9.73 at the end of the study compared to
baseline (95% CI, 8.38 to 11.08; p < 0.0001).
Discussion
Since the introduction of second-generation antipsy-
chotics in schizophrenia, there has been a change in the
strategy of treatment - from inpatient treatment of the
acute symptoms to outpatient maintenance treatment
and improved quality of life. The golden standard of
antipsychotic treatment should aim to achieve ‘clinical
Figure 1 Total mean values in CGI-S, CGI-I, PANSS, and BARS at baseline, visit 1, visit 2, and final visit. After 18 weeks of treatment.
Results for CGI-S, CGI-I, and BARS refer to the total population. PANSS refers only for these patients who demonstrated lack of efficacy as the
reason for treatment switching.
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the acute phase, thus reducing the risk for progressive
cognitive deterioration, functional disabilities, comorbid-
ities, and poor quality of life [29,30]. It has been shown
that lack of efficacy and tolerability, often associated
with poor compliance, results in treatment discontinu-
ation or treatment switch [8,31].
In our study, the switch to a second-generation anti-
psychotic monotherapy treatment led to a clinical bene-
fit which was achieved within an 18-week period by the
majority of the participants, irrespective of the reason(s)
for switch. Furthermore, all efficacy measures - total
PANSS, CGI-I, and CGI-S scores - were significantlyTable 3 Mean changes in weight, glucose, prolactin, and seru
Measurement Number Baseline, mean (SD)
Weight (kg) 149 89.6 (17.3)
Glucose (mmol/L) 17 48.3 (69.4)
Prolactin (ng/mL) 39 83.6 (48.7)
Total cholesterol (mmol/L) 11 81.7 (108.0)
LDL (mmol/L) 8 75.8 (92.2)
HDL (mmol/L) 10 37.4 (17.9)
Triglycerides (mmol/L) 10 124 (NA)
LDL, low-density lipoprotein; HDL, high-density lipoprotein; NA not applicable.improved, justifying the physicians’ choice of treatment.
Treatment switch was well tolerated by the majority of
the study participants; SAS scores as well as certain
metabolic parameters, such as body weight, glucose,
total cholesterol and prolactin levels, were significantly im-
proved. Notably, upon the decision to switch, the safety
profile of different antipsychotics must be taken into con-
sideration, as antipsychotic medications are known to have
varying degrees of adverse effects on body weight and can
lead to increased risk for diabetes and dyslipidaemia [32].
Furthermore, our study population showed increased ad-
herence to treatment, which was sustained throughout the
18 weeks of the study.m lipid levels from baseline to final visit
Final visit, mean (SD) Mean change p value
82.8 (16.0) −6.85 <0.0001
36.2 (49.8) −12.08 0.022
21.3 (10.8) −62.3 <0.0001
72.0 (96.2) −9.73 0.047
70.2 (84.4) −5.52 0.445
41.6 (17.7) 4.2 0.282
92.4 (112.3) −31.58 0.212
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ing between atypical antipsychotics is the occurrence of
side effects or withdrawal symptoms, many of which are
attributed to receptor profiles and antimuscarinic or an-
tihistaminic blockade [16]. In the ETOS study, tolerabil-
ity was only assessed in those patients experiencing
tolerability issues with their past medication. However,
as treatment switch was accompanied by increased com-
pliance in the majority of the study population, it can be
postulated that patients switched to another anti-
psychotic due to efficacy reasons did not experience
major side effects - i.e., extrapyramidal symptoms,
weight gain, or metabolic disorders - or withdrawal
symptoms, at least not to the extent that the possible
side effects might have interfered with the patients' ad-
herence to treatment. At the same time, patients that
were switched due to tolerability reasons showed in-
creased efficacy, a fact that may underline what has been
previously suggested, i.e., reducing side effects improves
tolerability and therefore may improve compliance,
which in turn may be translated into enhanced efficacy
[12,16].
Limitations of the study include its non-randomized
nature, which may have introduced bias. Secondly, the
fact that the majority of patients were switched to que-
tiapine makes it difficult to draw any conclusions from
head-to-head drug comparisons, which therefore have
been avoided; thirdly, physicians were not asked to regis-
ter the reasons for selecting a particular antipsychotic.
This lack of information prevents us from drawing firm
conclusions on the safety-specific characteristics of the
different antipsychotics that may guide physician deci-
sion making, especially in high-risk patients, such as
dyslipidaemic patients.
In conclusion, when an antipsychotic treatment shows
lack of efficacy or has tolerability issues, despite efforts
for optimal dosing and control of the associated side ef-
fects, switching to another single antipsychotic agent
may be efficacious, well tolerated, and may result in an
increased adherence to treatment. Once the decision on
switching therapy has been taken, the switching strategy
must be tailored to the individual patient characteristics
and environmental factors. The transition period is cru-
cial, as side effects to the new agent may be transient
and withdrawal symptoms may occur, and therefore,
both the physician and the family/caregiver should ac-
tively support the patient encouraging adherence and
persistence to treatment.Abbreviations
BARS: Brief adherence rating scale; CGI-CB: Clinical global impression-clinical
benefit; CGI-Ι: Clinical global impression-improvement; CGI-S: Clinical global
impression-severity; DSM-IV: Diagnostic and statistical manual of mental
disorders - 4th edition; PANSS: Positive and negative syndrome scale;
SAS: Simpson-angus scale.Competing interests
AR is an employee of AstraZeneca.
Authors’ contributions
AR and CK contributed substantially to the design and analysis of the study,
as well as to development and critical revision of the manuscript. DD, AT, II,
EM, TM, AS, and AY have contributed substantially to the interpretation of
the data and critical revision of the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
Medical writing support was provided by Krinio Palli of Qualitis Ltd funded
by AstraZeneca.
AstraZeneca led the design and the implementation and provided financial
support for the conduct and the analysis of the study. The study was
registered at clinicaltrials.gov as a non-interventional study (NCT00999895).
Author details
1AstraZeneca Greece, Athens 15125, Greece. 2Psychiatric Department,
Sismanoglio General Hospital, Athens 15126, Greece. 3Private Practice,
Thessaloniki 54623, Greece. 4Private Practice, Athens 11528, Greece. 5Private
Practice, Nafplio 21100, Greece. 6Aiginition Hospital, Athens 11528, Greece.
7Center for Mental Health, Kalamata 24100, Greece.
Received: 23 September 2013 Accepted: 3 December 2013
Published: 20 December 2013
References
1. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC: Lifetime prevalence,
demographic risk factors, and diagnostic validity of nonaffective
psychosis as assessed in a US community sample. The National
Comorbidity Survey. Arch Gen Psychiatry 1996, 53(11):1022.
2. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D:
A systematic review of the incidence of schizophrenia: the distribution
of rates and the influence of sex, urbanicity, migrant status and
methodology. BMC Med 2004, 2:13.
3. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW:
Medication adherence and long-term functional outcomes in the
treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67:453–460.
4. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR:
The cost of relapse and the predictors of relapse in the treatment of
schizophrenia. BMC Psychiatry 2010, 10:2.
5. Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S,
Akhras K, Jacobs A: Treatment retention with risperidone long-acting injection:
24-month results from the Electronic Schizophrenia Treatment Adherence
Registry (e-STAR) in six countries. Curr Med Res Opin 2010, 26:501–509.
6. Canadian Psychiatric Association: Clinical practice guidelines. Treatment of
schizophrenia. Can J Psychiatry 2005, 50(Suppl 1):7–57.
7. Cooper D, Moisan J, Grégoire JP: Adherence to atypical antipsychotic
treatment among newly treated patients: a population-based study in
schizophrenia. J Clin Psychiatry 2007, 68:818–825.
8. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO,
Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators:
Effectiveness of antipsychotic drugs in patients with chronic
schizophrenia. N Engl J Med 2005, 353:1209–1223.
9. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR: Treatment
adherence associated with conventional and atypical antipsychotics in a
large state Medicaid program. Psychiatr Serv 2003, 54:719–723.
10. Karagianis J, Williams R, Davis L, Procyshyn R, Monga N, Hanley J, Chandrasena
R, Thakur A, Dickson R: Antipsychotic switching: results from a one-year
prospective, observational study of patients with schizophrenia. Curr Med
Res Opin 2009, 25:2121–2132.
11. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM: Predictors and
clinical consequences of non-adherence with antipsychotic medication in the
outpatient treatment of schizophrenia. Psychiatry Res 2010, 176:109–113.
12. Goff DC, Hill M, Freudenreich O: Strategies for improving treatment
adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry
2010, 71(Suppl 2):20–26.
13. Nasrallah HA: The case for long-acting antipsychotic agents in the
post-CATIE era. Acta Psychiatr Scand 2007, 115:260–267.
Roussidis et al. Annals of General Psychiatry 2013, 12:42 Page 7 of 7
http://www.annals-general-psychiatry.com/content/12/1/4214. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE,
Chen L, Adams DH, Ascher-Svanum H, Buckley PF, Citrome L, Volavka J:
Medication nonadherence and treatment outcome in patients with
schizophrenia or schizoaffective disorder with suboptimal prior
response. J Clin Psychiatry 2009, 70:990–996.
15. Morken G, Widen JH, Grawe RW: Non-adherence to antipsychotic
medication, relapse and rehospitalisation in recent-onset schizophrenia.
BMC Psychiatry 2008, 8:32.
16. Buckley PF, Correll CU: Strategies for dosing and switching antipsychotics
for optimal clinical management. J Clin Psychiatry 2008, 69(Suppl 1):4–17.
17. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J,
Lieberman J: Does switching to a new antipsychotic improve outcomes?
Data from the CATIE Trial. Schizophr Res 2009, 107(1):22–29.
18. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL: Effectiveness of
switching to ziprasidone for stable but symptomatic outpatients with
schizophrenia. J Clin Psychiatry 2003, 64:580–588.
19. Loebel A, Siu C, Romano S: Improvement in prosocial functioning after a
switch to ziprasidone treatment. CNS Spectr 2004, 9:357–364.
20. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B,
Chakos M, McEvoy JP: Olanzapine in refractory schizophrenia after failure
of typical or atypical antipsychotic treatment: an open-label switch
study. J Clin Psychiatry 2002, 63:931–935.
21. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D, Study
147 Investigators: Switching from other antipsychotics to once-daily
extended release quetiapine fumarate in patients with schizophrenia.
Curr Med Res Opin 2008, 24(1):21–32.
22. De Nayer A, Windhager E, Irmansyah E, Larmo I, Lindenbauer B,
Rittmannsberger H, Platz T, Jones A, Whiteford J, Altman C: Efficacy and
tolerability of quetiapine in patients with schizophrenia switched from
other antipsychotics. Int J Psychiatry Clin Pract 2003, 7:59–66.
23. Weiden PJ: Switching antipsychotics: an updated review with a focus on
quetiapine. J Psychopharmacol 2006, 20:104–118.
24. Weiden PJ: EPS profiles: the atypical antipsychotics are not all the same.
J Psychiatr Pract 2007, 13:13–24.
25. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic
effects: a comprehensive literature review. CNS Drugs 2005, 19(suppl 1):1–93.
26. Tschoner A, Engl J, Rettenbacher M, Edlinger M, Kaser S, Tatarczyk T, Effenberger
M, Patsch JR, Fleischhacker WW, Ebenbichler CF: Effects of six second
generation antipsychotics on body weight and metabolism - risk assessment
and results from a prospective study. Pharmacopsychiatry 2009, 42(1):29–34.
27. Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids:
a comprehensive review. Schizophr Res 2004, 70:1–17.
28. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber
MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC: Glucose
metabolism in patients with schizophrenia treated with atypical
antipsychotic agents: a frequently sampled intravenous glucose tolerance
test and minimal model analysis. Arch Gen Psychiatry 2005, 62:19–28.
29. Altamura AC, Bobo WV, Meltzer HY: Factors affecting outcome in
schizophrenia and their relevance for psychopharmacological treatment.
Int Clin Psychopharm 2007, 22:249–267.
30. Altamura AC, Glick ID: Designing outcome studies to determine efficacy
and safety of antipsychotics for ‘real world’ treatment of schizophrenia.
Int J Neuropsychopharmacol 2010, 13(7):971–973.
31. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD,
Nyilas M, Iwamoto T, Crandall DT: A prospective, multicenter, randomized,
parallel-group, open-label study of aripiprazole in the management of
patients with schizophrenia or schizoaffective disorder in general
psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA).
Schizophr Res 2006, 84:77–89.
32. Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J: Metabolic
risk status and second-generation antipsychotic drug selection: a
retrospective study of commercially insured patients. J Clin Psychopharmacol
2009, 29:26Y32.
doi:10.1186/1744-859X-12-42
Cite this article as: Roussidis et al.: Reasons and clinical outcomes of
antipsychotic treatment switch in outpatients with schizophrenia in
real-life clinical settings: the ETOS observational study. Annals of General
Psychiatry 2013 12:42.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
